<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181489</url>
  </required_header>
  <id_info>
    <org_study_id>2019-SR-271</org_study_id>
    <nct_id>NCT04181489</nct_id>
  </id_info>
  <brief_title>Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS</brief_title>
  <official_title>A Phase II, Prospective, Multi-center Study of Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prognosis of EBV+ DLBCL is dismal. Previous study showed that high level of PD-L1
      expression in EBV+ DLBCL. The investigators therefore design this phase II study to
      investigate the safety and efficacy of sintilimab (an anti-PD-1 antibody) in combination with
      R-CHOP in patients with treatment-naive EBV+ DLBCL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progressive free survival</measure>
    <time_frame>2 years</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 months</time_frame>
    <description>overall response rate after treated by Sintilimab and R-CHOP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment related adverse events as assessed by NCI-CTCAE 5.0</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>EBV-Positive DLBCL, Nos</condition>
  <arm_group>
    <arm_group_label>Sintilimab + R-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Sintilimab 200mg d0</description>
    <arm_group_label>Sintilimab + R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m2 d0</description>
    <arm_group_label>Sintilimab + R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 750 mg/m2 d1</description>
    <arm_group_label>Sintilimab + R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 50 mg/m2 d1</description>
    <arm_group_label>Sintilimab + R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine 1.4mg/m2 (maximum 2mg) d1</description>
    <arm_group_label>Sintilimab + R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone 60mg/m2 d1-5</description>
    <arm_group_label>Sintilimab + R-CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Histologically confirmed EBV-positive diffuse large B cell lymphoma, NOS, according to
        WHO 2016 criteria.

        2. Understand and voluntarily sign an informed consent form, able to adhere to the study
        visit schedule and other protocol requirements.

        3. Undergo whole-body PET/CT scan 28 days before enrolment and have a measurable or
        evaluable disease (nodal lesion: diameter ≥ 1.5cm; extranodal lesion≥1.0cm）according to
        Lugano 2014 criteria； 4. ECOG PS 0- 2; 5. Adequate organ function, defined as:

          1. Blood routine test: neutrophil count ≥ 1.0×10⁹/L, platelet count ≥ 50×10⁹/L,
             hemoglobulin ≥8.0g/dL, without G-CSF usage or blood infusion within 7 days before
             examination.

          2. Hepatic function: total bilirubin less than 1.5-fold of upper normal level; ALT and
             AST less than 2-fold of upper normal level.

          3. Renal function: Serum creatine less than 1.5-fold of upper normal level or Ccr ≥ 50
             mL/min.

          4. Cardiac function: New York Heart Association class II or below (EF≥ 50% according to
             TDE)

          5. Coagulative function: INR less than 1.5-fold of upper normal level, APTT less than 10s
             above upper normal level and PT less than 3s above upper normal level;

          6. Thyroid function: normal baseline TSH level, or abnormal baseline TSH but normal T3/T4
             level without symptoms; 6. Expected survival ≥ 3 months; 7. Age 18~70 years; 8. Female
             subjects in childbearing age, their serum or urine pregnancy test must be negative.
             All patients must agree to take effective contraceptive measures during treatment and
             90 days after treatment.

        Exclusion Criteria:

          1. CNS or meningeal involvement;

          2. Patients with secondary tumour, excluding cured (5 years without relapse) in situ
             Non-melanoma skin cancer. superficial bladder cancer, in situ cervical cancer,
             Gastrointestinal intramucous carcinoma and breast cancer;

          3. Known sensitivity or allergy to investigational product;

          4. Previous exposure to anti PD-1 antibody, anti PD-L1 antibody, anti PD-L2 antibody,
             anti CTLA-4 antibody, CAR-T therapy or any T cell co-stimulating antibody or
             checkpoint inhibitor;

          5. Previous allogeneic organ transplantation or allogeneic stem cell transplantation;

          6. Intention to use any other anti-tumour therapy during treatment;

          7. Use of systemic anti-tumour treatment within 3 months before first dose of study
             regimen;

          8. Active and severe infectious diseases requiring systemic treatment;

          9. Active (known or suspected) autoimmune disease or history of autoimmune disease within
             2 years before treatment (excluding patients with leukoderma, psoriasis, lipsotrichia
             or Grave's disease who do not require systemic treatment within 2 years, patients with
             hypothyrea only requiring thyroxine as treatment, and patients with type I diabetes
             but only requiring insulin treatment)

         10. Usage of immune inhibitory drugs 4 weeks before the first dose of study regimen,
             excluding local usage of glucocorticoid and systemic usage of less than 10mg/d
             Prednisone or equivalent glucocorticoid.

         11. Active hepatitis B or hepatitis C virus infection, as well as acquired, congenital
             immune deficiency diseases, including but not limited to HIV-infected persons;

         12. Previous history of Idiopathic pulmonary fibrosis or Idiopathic pneumonia;

         13. Active tuberculosis;

         14. Presence of ≥ Grade 3 immune therapy related toxicity;

         15. History of mental disorder including epilepsia and dementia;

         16. Any anti-infectious vital vaccine usage 4 weeks before the first dose or during
             treatment;

         17. Any potential drug abuse, medical, psychological or social conditions which may
             disturb this investigation and assessment;

         18. Women who are pregnant or lactating.

         19. Usage of other experimental drugs within 1 month before treatment;

         20. In any conditions which investigator considered ineligible for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Xu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yi xia, M.D., Ph.D.</last_name>
    <phone>025-68306034</phone>
    <email>cynthia0311@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Xu, M.D., Ph.D.</last_name>
    <phone>025-68306034</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ChangZhou First People's Hospital</name>
      <address>
        <city>ChangZhou</city>
        <state>Jiangsu</state>
        <zip>213003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XiangShan Cao, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>XiangShan Cao, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ChangZhou No.2 People's Hospital</name>
      <address>
        <city>ChangZhou</city>
        <state>Jiangsu</state>
        <zip>213011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Zhou, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Min Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HuaiAn First People's Hospital</name>
      <address>
        <city>HuaiAn</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Yu, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Liang Yu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drum tower hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingyan Xu, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)</name>
      <address>
        <city>NanJing</city>
        <state>Jiangsu</state>
        <zip>21002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Xia, M.D., Ph.D.</last_name>
      <phone>+86 25 68136034</phone>
      <email>cynthia0311@163.com</email>
    </contact>
    <investigator>
      <last_name>Wei Xu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Nantong University</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenyu Shi, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bingzong Li, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>WuXi People's Hospital</name>
      <address>
        <city>WuXi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Zhuang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>YunFeng Shen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolin Li, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yancheng First People's Hospital</name>
      <address>
        <city>Yancheng</city>
        <state>Jiangsu</state>
        <zip>224000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Xu, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZhenJiang First People's Hospital</name>
      <address>
        <city>ZhenJiang</city>
        <state>Jiangsu</state>
        <zip>212002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Zhu, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Yan Zhu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15. Review.</citation>
    <PMID>26980727</PMID>
  </reference>
  <reference>
    <citation>Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010 Sep 23;116(12):2040-5. doi: 10.1182/blood-2010-03-276246. Epub 2010 Jun 14.</citation>
    <PMID>20548096</PMID>
  </reference>
  <reference>
    <citation>Ahn JS, Yang DH, Duk Choi Y, Jung SH, Yhim HY, Kwak JY, Sung Park H, Shin MG, Kim YK, Kim HJ, Lee JJ. Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. Am J Hematol. 2013 Sep;88(9):774-9. doi: 10.1002/ajh.23507. Epub 2013 Jul 23.</citation>
    <PMID>23760676</PMID>
  </reference>
  <reference>
    <citation>Sato A, Nakamura N, Kojima M, Ohmachi K, Carreras J, Kikuti YY, Numata H, Ohgiya D, Tazume K, Amaki J, Moriuchi M, Miyamoto M, Aoyama Y, Kawai H, Ichiki A, Hara R, Kawada H, Ogawa Y, Ando K. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. Cancer Sci. 2014 Sep;105(9):1170-5. doi: 10.1111/cas.12467. Epub 2014 Sep 8.</citation>
    <PMID>24974976</PMID>
  </reference>
  <reference>
    <citation>Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, Jo J, Jung SH, Hong ME, Yoon H, Ko YH, Kim SJ, Kim WS. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol. 2015 Mar;26(3):548-55. doi: 10.1093/annonc/mdu556. Epub 2014 Dec 4.</citation>
    <PMID>25475080</PMID>
  </reference>
  <reference>
    <citation>Lu TX, Liang JH, Miao Y, Fan L, Wang L, Qu XY, Cao L, Gong QX, Wang Z, Zhang ZH, Xu W, Li JY. Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep. 2015 Jul 23;5:12168. doi: 10.1038/srep12168.</citation>
    <PMID>26202875</PMID>
  </reference>
  <reference>
    <citation>Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018 Jan 4;131(1):68-83. doi: 10.1182/blood-2017-07-740993. Epub 2017 Nov 8. Review.</citation>
    <PMID>29118007</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Sintilimab</keyword>
  <keyword>R-CHOP</keyword>
  <keyword>EBV-Positive DLBCL, nos</keyword>
  <keyword>treatment-naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

